Novel therapy may prove effective in treatment of 30 percent of cancers

	Tweet

A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.

The study, inspired by the exciting discoveries made by Dr. Borden at IRIC, was a joint project between her research group, who monitored molecular events in trial patients, and Dr. Sarit Assouline of the Segal Cancer Centre, Jewish General Hospital, who led the clinical part of the trial.

The integration of these two teams made it possible to rapidly move from a research lab to patient tests. The study team targeted the gene by giving trial participants a mimic of its natural target, ribavirin. “Our results are the first to show that targeting eIF4E in humans is clinically beneficial,” explains Dr. Borden. “We also found that ribavirin not only blocks eIF4E, it has no side effect on patients.”

The trial studied patients with M4/M5 acute myeloid leukemia who had undergone several other treatments that had previously failed. “We had striking clinical improvements with even partial and complete remissions,” indicated Assouline.

Dr. Wilson Miller, director of the Clinical Research Unit, Jewish General Hospital, and co-investigator in the trial added: “It’s rare that discoveries in basic research move to clinical so quickly and successfully.”

The next challenge for this team is to overcome the resistance that develops over time to ribavirin. “Combination therapy with chemotherapeutic agents may enhance the efficacy of this treatment,” explains Borden, “Trials in the near future are planned to overcome this and we are looking forward to more complete remissions. We also hope to test whether ribavirin is as effective in the treatment of other cancers with dysregulated eIF4E. Our laboratory studies suggest this is likely.”

The study team also included Drs. Brian Leber from McMaster University/Hamilton Health Sciences (Ontario) and Denis-Claude Roy from Hôpital Maisonneuve-Rosemont in Montreal. The study was made possible thanks to a $600,000 grant awarded to Dr. Borden by The Leukemia and Lymphoma Society (USA).

###

About the Institute for Research in Immunology and Cancer

IRIC is a state-of-the-art biomedical research at the Université de Montréal. IRIC is committed to finding novel cancer therapeutics through multidisciplinary approaches. Its team of more than 350 scientists and professionals work on various aspects of cancer research from basic science through to clinical applications. For more information about IRIC, please visit http://www.iric.ca. For more information about Dr. Katherine Borden, please visit http://www.iric.ca/Recherche/Chercheurs/Borden_K_EN.html

About the Segal Cancer Centre at the Jewish General Hospital

The Centre is at the forefront of cancer services in Quebec, implementing a focused and comprehensive approach to fighting cancer through medical treatment, patient care, family support and scientific research. Basic and clinical research are a leading priority for the Centre, which has the largest number of clinician-scientists in cancer in Quebec and offers patients the latest clinical trials.

Paper cited:

Sarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, Caroline Rousseau, Nathalie Beslu, Abdellatif Amri, Stephen Caplan, Brian Leber, Denis-Claude Roy, Wilson H. Miller Jr, and Katherine L.B. Borden. “Molecular targeting of the oncogene eIF4E in AML: a proof-of-principle clinical trial with ribavirin” Blood First Edition Paper, prepublished online May 11, 2009; DOI 10.1182/blood-2009-02-205153

Contact: Carolyne Lord

514-343-7282
University of Montreal

RELATED STORIES:
Cancer society challenges Americans to get active   More Allergic Reactions to Widely-Used Cancer Drug   Researchers unveil vital key to cancer   Scientists Find Key to Gene that Promotes Cancer Metastasis   Cancer patient takes trust court   Inhaled morphine eases cancer-related air hunger   Mobile phones don’t hike cancer risk: Danish study   Fruit research yields way to curb cancer   Childhood cancer survivors face limitations   Black raspberries slow cancer by altering hundreds of genes   Amgen, Abgenix antibody curbs colon cancer   Music-based “Play” Helps Young Cancer Patients Cope   New era in cancer prevention   Europe aims to reduce cancer deaths by 15 pct by 2020   Cancer Staging Takes Cues from Embryonic Development   Childhood cancer mortality high in UK in children   Is there an increased risk of other malignancies in patients with renal cell carcinoma?   Co-ordinating cancer care   And the number one cancer myth is…   Getting down to cancer basics   Only five percent of cancer research funds are spent on metastases, yet it kills 90 percent of all cancer patients   Scientists develop new approach for cancer vaccine

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]